Status:
RECRUITING
New Screening and Diagnostic Cut-off Points of PA Patients
Lead Sponsor:
China National Center for Cardiovascular Diseases
Collaborating Sponsors:
Beijing Anzhen Hospital
First Affiliated Hospital of Chongqing Medical University
Conditions:
Primary Aldosteronism
Eligibility:
All Genders
18-75 years
Brief Summary
This study aims to establish the screening and diagnostic cut-off points for primary aldosteronism patients by a novel small molecule "sandwich method" aldosterone and renin chemiluminescent immunoass...
Detailed Description
Primary aldosteronism (PA) is the most common causes of secondary hypertension. The diagnostic workup for PA is composed of multiple steps and requires measurement of both plasma aldosterone and renin...
Eligibility Criteria
Inclusion
- 18-75y;
- persistent hypertension (BP \>150/100 mm Hg), or drug-resistant hypertension;
- newly diagnosed hypertension;
- hypertension and spontaneous or diuretic-induced hypokalemia;
- hypertension with adrenal incidentaloma;
- hypertension and a family history of early-onset hypertension or cerebrovascular accident at a young age (\<40 years);
- status as a hypertensive first-degree relative of patients with PA;
- patients with hypertension and obstructive sleep apnea.
Exclusion
- age \<18; BMI ≤ 18.0kg/m2 or ≥ 35.0 kg/m2;
- a diagnosis of secondary hypertension other than PA;
- chronic cardiac dysfunction (NYHA III-IV);
- medium and several kidney dysfunction (Ccr\<30ml/min);
- liver cirrhosis;
- terminal malignant tumor;
- recent use of steroids or oral contraceptives;
- pregnancy or lactation.
Key Trial Info
Start Date :
January 4 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
770 Patients enrolled
Trial Details
Trial ID
NCT06571084
Start Date
January 4 2024
End Date
December 31 2025
Last Update
August 26 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Kai-juan Wang
Beijing, China, 100037